Olema Pharmaceuticals (OLMA) Projected to Post Quarterly Earnings on Tuesday

Olema Pharmaceuticals (NASDAQ:OLMA) is expected to be posting its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.44) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 18, 2025 at 7:00 AM ET.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, August 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.08). On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

OLMA stock traded up $0.02 on Tuesday, hitting $8.44. The company had a trading volume of 137,333 shares, compared to its average volume of 970,730. Olema Pharmaceuticals has a 12-month low of $2.86 and a 12-month high of $13.51. The company has a current ratio of 11.09, a quick ratio of 11.09 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $8.54 and its 200 day simple moving average is $6.11. The stock has a market cap of $579.00 million, a price-to-earnings ratio of -4.26 and a beta of 2.08.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $8.33, for a total transaction of $83,300.00. Following the transaction, the director owned 744,140 shares in the company, valued at approximately $6,198,686.20. The trade was a 1.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 25,000 shares of company stock worth $204,841. 16.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. American Century Companies Inc. bought a new stake in Olema Pharmaceuticals in the 2nd quarter valued at $54,000. Creative Planning purchased a new stake in Olema Pharmaceuticals in the 2nd quarter worth about $83,000. The Manufacturers Life Insurance Company raised its position in Olema Pharmaceuticals by 46.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,442 shares of the company’s stock worth $96,000 after purchasing an additional 7,146 shares during the period. AQR Capital Management LLC purchased a new stake in Olema Pharmaceuticals in the 1st quarter worth about $172,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Olema Pharmaceuticals in the 2nd quarter worth about $213,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Oppenheimer restated an “outperform” rating and issued a $22.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, September 3rd. Zacks Research upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of Olema Pharmaceuticals in a research note on Monday, October 20th. JPMorgan Chase & Co. lifted their price target on shares of Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Thursday, August 14th. Finally, Guggenheim started coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. They set a “buy” rating and a $20.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.